Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCS.
Page 1: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1 | 8 | 29 | 424 1994 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91(9):4082-4085 DAMATO RJ; LOUGHNAN MS; FLYNN E; FOLKMAN J THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS | 333 | 732 |
2 | 9 | 37 | 852 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
3 | 2 | 25 | 309 1991 JOURNAL OF EXPERIMENTAL MEDICINE 173(3):699-703 SAMPAIO EP; SARNO EN; GALILLY R; COHN ZA; KAPLAN G THALIDOMIDE SELECTIVELY INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY STIMULATED HUMAN MONOCYTES | 291 | 504 |
4 | 1 | 19 | 364 1993 JOURNAL OF EXPERIMENTAL MEDICINE 177(6):1675-1680 MOREIRA AL; SAMPAIO EP; ZMUIDZINAS A; FRINDT P; SMITH KA; KAPLAN G THALIDOMIDE EXERTS ITS INHIBITORY-ACTION ON TUMOR-NECROSIS-FACTOR-ALPHA BY ENHANCING MESSENGER-RNA DEGRADATION | 236 | 431 |
5 | 8 | 21 | 334 1992 NEW ENGLAND JOURNAL OF MEDICINE 326(16):1055-1058 VOGELSANG GB; FARMER ER; HESS AD; ALTAMONTE V; BESCHORNER WE; JABS DA; CORIO RL; LEVIN LS; COLVIN OM; WINGARD JR; SANTOS GW THALIDOMIDE FOR THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE | 166 | 253 |
6 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
7 | 1 | 23 | 365 1993 JOURNAL OF INFECTIOUS DISEASES 168(2):408-414 SAMPAIO EP; KAPLAN G; MIRANDA A; NERY JAC; MIGUEL CP; VIANA SM; SARNO EN THE INFLUENCE OF THALIDOMIDE ON THE CLINICAL AND IMMUNOLOGICAL MANIFESTATION OF ERYTHEMA-NODOSUM LEPROSUM | 141 | 212 |
8 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
9 | 13 | 34 | 447 1995 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 99(2):160-167 MCHUGH SM; RIFKIN IR; DEIGHTON J; WILSON AB; LACHMANN PJ; LOCKWOOD CM; EWAN PW THE IMMUNOSUPPRESSIVE DRUG THALIDOMIDE INDUCES T-HELPER CELL-TYPE 2 (TH2) AND CONCOMITANTLY INHIBITS TH1 CYTOKINE PRODUCTION IN MITOGEN-STIMULATED AND ANTIGEN-STIMULATED HUMAN PERIPHERAL-BLOOD MONONUCLEAR CELL-CULTURES | 108 | 145 |
10 | 1 | 24 | 376 1993 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 90(13):5974-5978 MAKONKAWKEYOON S; LIMSONPOBRE RNR; MOREIRA AL; SCHAUF V; KAPLAN G THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 | 105 | 184 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
11 | 11 | 41 | 600 1997 EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 97 | 150 |
12 | 10 | 31 | 896 2000 BLOOD 96(9):2943-2950 Hideshima T; Chauhan D; Shima Y; Raje N; Davies FE; Tai YT; Treon SP; Lin B; Schlossman RL; Richardson P; Muller G; Stirling DI; Anderson KC Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy | 90 | 173 |
13 | 8 | 19 | 948 2000 BRITISH JOURNAL OF HAEMATOLOGY 109(1):89-96 Juliusson G; Celsing F; Turesson I; Lenhoff S; Adriansson M; Malm C Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma | 88 | 117 |
14 | 2 | 54 | 48 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
15 | 11 | 27 | 670 1998 BIOCHEMICAL PHARMACOLOGY 55(11):1827-1834 Bauer KS; Dixon SC; Figg WD Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent | 82 | 122 |
16 | 10 | 48 | 827 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
17 | 1 | 8 | 68 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):461-466 KNOP J; BONSMANN G; HAPPLE R; LUDOLPH A; MATZ DR; MIFSUD EJ; MACHER E THALIDOMIDE IN THE TREATMENT OF 60 CASES OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 78 | 109 |
18 | 74 | 101 | 546 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 78 | 117 |
19 | 11 | 38 | 945 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 78 | 130 |
20 | 6 | 34 | 1003 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
21 | 9 | 24 | 257 1989 DRUG METABOLISM AND DISPOSITION 17(4):402-405 CHEN TL; VOGELSANG GB; PETTY BG; BRUNDRETT RB; NOE DA; SANTOS GW; COLVIN OM PLASMA PHARMACOKINETICS AND URINARY-EXCRETION OF THALIDOMIDE AFTER ORAL DOSING IN HEALTHY MALE-VOLUNTEERS | 77 | 81 |
22 | 10 | 30 | 621 1997 JOURNAL OF IMMUNOLOGY 159(10):5157-5161 Moller DR; Wysocka M; Greenlee BM; Ma XJ; Wahl L; Flockhart DA; Trinchieri G; Karp CL Inhibition of IL-12 production by thalidomide | 77 | 114 |
23 | 9 | 28 | 531 1996 IMMUNOPHARMACOLOGY 31(2-3):213-221 Geitz H; Handt S; Zwingenberger K Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade | 75 | 94 |
24 | 12 | 23 | 382 1994 ARCHIVES OF DERMATOLOGY 130(1):66-69 OCHONISKY S; VERROUST J; BASTUJIGARIN S; GHERARDI R; REVUZ J THALIDOMIDE NEUROPATHY INCIDENCE AND CLINICOELECTROPHYSIOLOGIC FINDINGS IN 42 PATIENTS | 73 | 97 |
25 | 9 | 21 | 1094 2001 BLOOD 98(2):492-494 Barlogie B; Desikan R; Eddlemon P; Spencer T; Zeldis J; Munshi N; Badros A; Zangari M; Anaissie E; Epstein J; Shaughnessy J; Ayers D; Spoon D; Tricot G Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients | 68 | 113 |
26 | 11 | 25 | 660 1998 ANNALS OF INTERNAL MEDICINE 128(6):443-+ Hamuryudan V; Mat C; Saip S; Ozyazgan Y; Siva A; Yurdakul S; Zwingenberger K; Yazici H Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome - A randomized, double-blind, placebo-controlled trial | 67 | 127 |
27 | 4 | 30 | 142 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
28 | 10 | 25 | 849 1999 NATURE MEDICINE 5(5):582-585 Parman T; Wiley MJ; Wells PG Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity | 65 | 111 |
29 | 3 | 5 | 1096 2001 BLOOD 98(5):1614-1615 Zangari M; Anaissie E; Barlogie B; Badros A; Desikan R; Gopal AV; Morris C; Toor A; Siegel E; Fink L; Tricot G Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy | 63 | 94 |
30 | 4 | 18 | 478 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 131 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
31 | 62 | 96 | 877 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
32 | 0 | 8 | 2 1980 ARCHIVES OF DERMATOLOGICAL RESEARCH 269(3):275-280 FAURE M; THIVOLET J; GAUCHERAND M INHIBITION OF PMN LEUKOCYTES CHEMOTAXIS BY THALIDOMIDE | 59 | 70 |
33 | 11 | 20 | 301 1991 BRITISH JOURNAL OF HAEMATOLOGY 78(1):23-27 HENEY D; NORFOLK DR; WHEELDON J; BAILEY CC; LEWIS IJ; BARNARD DL THALIDOMIDE TREATMENT FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 59 | 72 |
34 | 0 | 0 | 320 1992 DRUG SAFETY 7(2):116-134 GUNZLER V THALIDOMIDE IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) PATIENTS - A REVIEW OF SAFETY CONSIDERATIONS | 59 | 75 |
35 | 14 | 25 | 445 1995 CHIRALITY 7(1):44-52 ERIKSSON T; BJORKMAN S; ROTH B; FYGE A; HOGLUND P STEREOSPECIFIC DETERMINATION, CHIRAL INVERSION IN-VITRO AND PHARMACOKINETICS IN HUMANS OF THE ENANTIOMERS OF THALIDOMIDE | 57 | 80 |
36 | 3 | 5 | 256 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
37 | 8 | 27 | 416 1994 LIFE SCIENCES 55(2):77-92 NOGUEIRA AC; NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .3. SIMULTANEOUS UP-REGULATION AND DOWN-REGULATION OF DIFFERENT INTEGRIN RECEPTORS ON HUMAN WHITE BLOOD-CELLS | 56 | 63 |
38 | 10 | 28 | 1023 2000 MAYO CLINIC PROCEEDINGS 75(9):897-901 Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Kyle RA; Gertz MA; Greipp PR Thalidomide in the treatment of relapsed multiple myeloma | 56 | 85 |
39 | 22 | 61 | 117 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
40 | 7 | 27 | 261 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
41 | 15 | 26 | 268 1990 ARCHIVES OF DERMATOLOGY 126(7):923-927 REVUZ J; GUILLAUME JC; JANIER M; HANS P; MARCHAND C; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DALLAC S; KLENE C; CRICKX B; SANCHOGARNIER H; CHAUMEIL JC CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN SEVERE RECURRENT APHTHOUS STOMATITIS | 53 | 100 |
42 | 7 | 22 | 380 1994 ANNALS OF THE RHEUMATIC DISEASES 53(12):828-832 GARDNERMEDWIN JMM; SMITH NJ; POWELL RJ CLINICAL-EXPERIENCE WITH THALIDOMIDE IN THE MANAGEMENT OF SEVERE ORAL AND GENITAL ULCERATION IN CONDITIONS SUCH AS BEHCETS-DISEASE - USE OF NEUROPHYSIOLOGICAL STUDIES TO DETECT THALIDOMIDE NEUROPATHY | 53 | 73 |
43 | 1 | 7 | 947 2000 BRITISH JOURNAL OF HAEMATOLOGY 108(2):391-393 Kneller A; Raanani P; Hardan I; Avigdor A; Levi I; Berkowicz M; Ben-Bassat I Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug | 53 | 75 |
44 | 6 | 25 | 439 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
45 | 6 | 33 | 540 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 126 |
46 | 0 | 7 | 165 1985 LEPROSY REVIEW 56(1):35-39 GAD SM; SHANNON EJ; KROTOSKI WA; HASTINGS RC THALIDOMIDE INDUCES IMBALANCES IN LYMPHOCYTE-T SUB-POPULATIONS IN THE CIRCULATING BLOOD OF HEALTHY-MALES | 50 | 65 |
47 | 9 | 18 | 1093 2001 BLOOD 98(1):210-216 Davies FE; Raje N; Hideshima T; Lentzsch S; Young G; Tai YT; Lin B; Podar K; Gupta D; Chauhan D; Treon SP; Richardson PG; Schlossman RL; Morgan GJ; Muller GW; Stirling DI; Anderson KC Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma | 50 | 94 |
48 | 5 | 38 | 490 1996 AIDS 10(13):1501-1507 ReyesTeran G; SierraMadero JG; delCerro VM; ArroyoFigueroa H; Pasquetti A; Calva JJ; RuizPalacios GM Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial | 49 | 98 |
49 | 0 | 24 | 26 1981 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES 78(4):2545-2548 GORDON GB; SPIELBERG SP; BLAKE DA; BALASUBRAMANIAN V THALIDOMIDE TERATOGENESIS - EVIDENCE FOR A TOXIC ARENE OXIDE METABOLITE | 48 | 89 |
50 | 14 | 44 | 469 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
51 | 8 | 17 | 853 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1606-1609 Raje N; Anderson K Thalidomide - A revival story. | 48 | 87 |
52 | 2 | 24 | 108 1984 ARTHRITIS AND RHEUMATISM 27(10):1118-1121 GUTIERREZRODRIGUEZ O THALIDOMIDE - A PROMISING NEW TREATMENT FOR RHEUMATOID-ARTHRITIS | 47 | 56 |
53 | 1 | 20 | 199 1986 TRANSPLANTATION 41(5):644-647 VOGELSANG GB; HESS AD; GORDON G; SANTOS GW TREATMENT AND PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH THALIDOMIDE IN A RAT MODEL | 47 | 71 |
54 | 17 | 33 | 359 1993 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 11(5):487-493 ATRA E; SATO EI TREATMENT OF THE CUTANEOUS LESIONS OF SYSTEMIC LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 47 | 65 |
55 | 3 | 4 | 1249 2001 NEW ENGLAND JOURNAL OF MEDICINE 344(25):1951-1952 Osman K; Comenzo R; Rajkumar SV Deep venous thrombosis and thalidomide therapy for multiple myeloma. | 46 | 59 |
56 | 13 | 67 | 1004 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 45 | 83 |
57 | 8 | 39 | 119 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 44 | 50 |
58 | 3 | 9 | 324 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 44 | 44 |
59 | 6 | 21 | 550 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 44 | 63 |
60 | 20 | 33 | 807 1999 GASTROENTEROLOGY 117(6):1271-1277 Ehrenpreis ED; Kane SV; Cohen LB; Cohen RD; Hanauer SB Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial | 44 | 132 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
61 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
62 | 0 | 4 | 39 1982 ARCHIVES OF DERMATOLOGY 118(8):536-536 SAYLAN T; SALTIK I THALIDOMIDE IN THE TREATMENT OF BEHCETS SYNDROME | 42 | 59 |
63 | 0 | 20 | 106 1984 ARCHIVES OF DERMATOLOGY 120(3):338-341 CLEMMENSEN OJ; OLSEN PZ; ANDERSEN KE THALIDOMIDE NEUROTOXICITY | 41 | 59 |
64 | 7 | 61 | 247 1988 TERATOLOGY 38(3):229-239 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 40 | 64 |
65 | 31 | 89 | 351 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
66 | 6 | 36 | 518 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 40 | 57 |
67 | 10 | 32 | 557 1996 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 93(15):7552-7556 Turk BE; Jiang H; Liu JO Binding of thalidomide to alpha(1)-acid glyeoprotein may be involved in its inhibition of tumor necrosis factor alpha production | 40 | 50 |
68 | 0 | 8 | 244 1988 TERATOLOGY 38(3):203-215 LENZ W A SHORT HISTORY OF THALIDOMIDE EMBRYOPATHY | 39 | 70 |
69 | 11 | 17 | 315 1991 TRANSPLANTATION 52(5):908-910 KEENAN RJ; EIRAS G; BURCKART GJ; STUART RS; HARDESTY RL; VOGELSANG G; GRIFFITH BP; ZEEVI A IMMUNOSUPPRESSIVE PROPERTIES OF THALIDOMIDE - INHIBITION OF INVITRO LYMPHOCYTE-PROLIFERATION ALONE AND IN COMBINATION WITH CYCLOSPORINE OR FK506 | 39 | 44 |
70 | 4 | 13 | 423 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):901-904 POWELL RJ; GARDNERMEDWIN JMM GUIDELINE FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 39 | 53 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
71 | 13 | 27 | 701 1998 GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY 236(6):461-466 Kruse FE; Joussen AM; Rohrschneider K; Becker MD; Volcker HE Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor | 39 | 57 |
72 | 8 | 28 | 726 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 79 |
73 | 1 | 17 | 796 1999 CLINICAL THERAPEUTICS 21(2):319-330 Zeldis JB; Williams BA; Thomas SD; Elsayed ME STEPS (TM): A comprehensive program for controlling and monitoring access to thalidomide | 39 | 47 |
74 | 21 | 40 | 1005 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
75 | 23 | 38 | 450 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
76 | 38 | 52 | 813 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
77 | 12 | 43 | 567 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
78 | 7 | 25 | 568 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(12):1047-1054 Haslett P; Hempstead M; Seidman C; Diakun J; Vasquez D; Freedman VH; Kaplan G The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus | 36 | 57 |
79 | 16 | 23 | 583 1997 BRITISH JOURNAL OF RHEUMATOLOGY 36(3):353-359 Stevens RJ; Andujar C; Edwards CJ; Ames PRJ; Barwick AR; Khamashta MA; Hughes GRV Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients | 36 | 49 |
80 | 19 | 33 | 703 1998 IMMUNOPHARMACOLOGY 40(1):11-20 Rowland TL; McHugh SM; Deighton J; Dearman RJ; Ewan PW; Kimber I Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells | 36 | 48 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
81 | 3 | 35 | 107 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 35 | 39 |
82 | 2 | 5 | 631 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 35 | 53 |
83 | 8 | 25 | 463 1995 IMMUNOPHARMACOLOGY 31(1):109-116 SHANNON EJ; SANDOVAL F THALIDOMIDE INCREASES THE SYNTHESIS OF IL-2 IN CULTURES OF HUMAN MONONUCLEAR-CELLS STIMULATED WITH CONCANAVALIN-A, STAPHYLOCOCCAL-ENTEROTOXIN-A, AND PURIFIED PROTEIN DERIVATIVE | 34 | 37 |
84 | 14 | 26 | 543 1996 JOURNAL OF MEDICINAL CHEMISTRY 39(17):3238-3240 Muller GW; Corral LG; Shire MG; Wang H; Moreira A; Kaplan G; Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity | 34 | 49 |
85 | 14 | 30 | 709 1998 JOURNAL OF IMMUNOLOGY 161(8):4236-4243 Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production | 34 | 50 |
86 | 16 | 28 | 834 1999 JOURNAL OF PHARMACEUTICAL SCIENCES 88(1):121-125 Figg WD; Raje S; Bauer KS; Tompkins A; Venzon D; Bergan R; Chen A; Hamilton M; Pluda J; Reed E Pharmacokinetics of thalidomide in an elderly prostate cancer population | 34 | 48 |
87 | 64 | 215 | 541 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
88 | 27 | 53 | 1219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
89 | 21 | 37 | 1490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
90 | 0 | 36 | 29 1981 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 13(6):553-562 SHANNON EJ; MIRANDA RO; MORALES MJ; HASTINGS RC INHIBITION OF DENOVO IGM ANTIBODY-SYNTHESIS BY THALIDOMIDE AS A RELEVANT MECHANISM OF ACTION IN LEPROSY | 32 | 41 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
91 | 3 | 4 | 234 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
92 | 8 | 27 | 333 1992 LIFE SCIENCES 51(26):2107-2116 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .2. CHANGES IN RECEPTORS ON BLOOD-CELLS OF A HEALTHY VOLUNTEER | 32 | 38 |
93 | 7 | 22 | 1740 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 32 | 59 |
94 | 1 | 20 | 154 1985 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 53(2):201-205 MONCADA B; BARANDA ML; GONZALEZAMARO R; URBINA R; LOREDO CE THALIDOMIDE - EFFECT ON T-CELL SUBSETS AS A POSSIBLE MECHANISM OF ACTION | 31 | 42 |
95 | 5 | 19 | 227 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
96 | 3 | 6 | 367 1993 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 28(2):271-272 GHIGLIOTTI G; REPETTO T; FARRIS A; ROY MT; DEMARCHI R THALIDOMIDE - TREATMENT OF CHOICE FOR APHTHOUS ULCERS IN PATIENTS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS | 31 | 39 |
97 | 1 | 8 | 43 1982 BRITISH JOURNAL OF DERMATOLOGY 107(1):83-86 NAAFS B; BAKKERS EJM; FLINTERMAN J; FABER WR THALIDOMIDE TREATMENT OF SUB-ACUTE CUTANEOUS LUPUS-ERYTHEMATOSUS | 30 | 44 |
98 | 5 | 11 | 848 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
99 | 5 | 13 | 1075 2001 ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 30 | 41 |
100 | 11 | 33 | 404 1994 EUROPEAN JOURNAL OF DERMATOLOGY 4(1):9-15 OCHONISKY S; REVUZ J THALIDOMIDE USE IN DERMATOLOGY | 29 | 34 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
101 | 6 | 18 | 499 1996 ANTI-CANCER DRUGS 7(3):339-343 Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MMM The effect of thalidomide on experimental tumors and metastases | 29 | 50 |
102 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
103 | 20 | 98 | 954 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
104 | 12 | 59 | 1095 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 29 | 64 |
105 | 4 | 25 | 442 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 28 | 44 |
106 | 13 | 22 | 517 1996 CHIRALITY 8(5):390-396 Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues | 28 | 34 |
107 | 10 | 19 | 1239 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
108 | 11 | 24 | 150 1985 INTERNATIONAL JOURNAL OF DERMATOLOGY 24(2):131-134 NAAFS B; FABER WR THALIDOMIDE THERAPY - AN OPEN TRIAL | 27 | 36 |
109 | 2 | 15 | 198 1986 TOXICOLOGY AND APPLIED PHARMACOLOGY 82(1):175-179 BRAUN AG; HARDING FA; WEINREB SL TERATOGEN METABOLISM - THALIDOMIDE ACTIVATION IS MEDIATED BY CYTOCHROME-P-450 | 27 | 34 |
110 | 5 | 7 | 329 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
111 | 6 | 11 | 384 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 27 | 44 |
112 | 14 | 23 | 681 1998 BONE MARROW TRANSPLANTATION 21(6):577-581 Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasiulli A; Vassallo E; Miniero R; Uderzo C The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children | 27 | 37 |
113 | 12 | 39 | 746 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
114 | 6 | 17 | 828 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
115 | 41 | 120 | 971 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
116 | 6 | 28 | 187 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
117 | 3 | 5 | 235 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
118 | 1 | 4 | 311 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
119 | 2 | 11 | 123 1984 LANCET 2(8417):1424-1426 JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL; SMITH NJ THALIDOMIDE IN SEVERE OROGENITAL ULCERATION | 25 | 35 |
120 | 3 | 18 | 156 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
121 | 5 | 19 | 176 1986 ARCHIVES OF INTERNAL MEDICINE 146(5):878-881 JORIZZO JL; SCHMALSTIEG FC; SOLOMON AR; CAVALLO T; TAYLOR RS; RUDLOFF HB; SCHMALSTIEG EJ; DANIELS JC THALIDOMIDE EFFECTS IN BEHCETS-SYNDROME AND PUSTULAR VASCULITIS | 25 | 59 |
122 | 23 | 42 | 388 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
123 | 0 | 0 | 452 1995 DRUG SAFETY 12(6):364-369 SCHULER U; EHNINGER G THALIDOMIDE - RATIONALE FOR RENEWED USE IN IMMUNOLOGICAL DISORDERS | 25 | 36 |
124 | 8 | 16 | 566 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(4):301-304 Alexander LN; Wilcox CM A prospective trial of thalidomide for the treatment of HIV-associated idiopathic esophageal ulcers | 25 | 32 |
125 | 8 | 20 | 880 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(2):171-174 Flageul B; Wallach D; Cavelier-Balloy B; Bachelez H; Carsuzaa F; Dubertret L Thalidomide and thrombosis. | 25 | 27 |
126 | 4 | 17 | 1170 2001 CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 25 | 60 |
127 | 7 | 27 | 1200 2001 HAEMATOLOGICA 86(4):399-403 Palumbo A; Giaccone L; Bertola A; Pregno P; Bringhen S; Rus C; Triolo S; Gallo E; Pileri A; Boccadoro M Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma | 25 | 38 |
128 | 2 | 6 | 217 1987 TRANSPLANTATION PROCEEDINGS 19(1):2658-2661 VOGELSANG GB; HESS AD; GORDON G; BRUNDRETTE R; SANTOS GW THALIDOMIDE INDUCTION OF BONE-MARROW TRANSPLANTATION TOLERANCE | 24 | 32 |
129 | 6 | 9 | 335 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(3):208-209 RYAN J; COLMAN J; PEDERSEN J; BENSON E THALIDOMIDE TO TREAT ESOPHAGEAL ULCER IN AIDS | 24 | 33 |
130 | 5 | 13 | 519 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
131 | 5 | 32 | 648 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 24 | 39 |
132 | 16 | 27 | 715 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 24 | 25 |
133 | 26 | 174 | 893 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
134 | 17 | 41 | 348 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
135 | 4 | 6 | 1033 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
136 | 0 | 10 | 1051 2000 SEMINARS IN HEMATOLOGY 37(1):22-25 Alexanian R; Weber D Thalidomide for resistant and relapsing myeloma | 23 | 27 |
137 | 5 | 21 | 1201 2001 HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
138 | 63 | 112 | 1298 2002 ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 23 | 36 |
139 | 2 | 21 | 69 1983 BRITISH JOURNAL OF DERMATOLOGY 108(4):467-471 LOVELL CR; HAWK JLM; CALNAN CD; MAGNUS IA THALIDOMIDE IN ACTINIC PRURIGO | 22 | 42 |
140 | 0 | 12 | 211 1987 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 413:181-187 CZEJKA MJ; KOCH HP DETERMINATION OF THALIDOMIDE AND ITS MAJOR METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 22 | 23 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
141 | 25 | 61 | 378 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 22 | 27 |
142 | 12 | 21 | 576 1997 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 41(12):2797-2799 Piscitelli SC; Figg WD; Hahn B; Kelly G; Thomas S; Walker RE Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients | 22 | 25 |
143 | 11 | 25 | 592 1997 CLINICAL INFECTIOUS DISEASES 24(6):1223-1227 Haslett P; Tramontana J; Burroughs M; Hempstead M; Kaplan G Adverse reactions to thalidomide in patients infected with human immunodeficiency virus | 22 | 30 |
144 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
145 | 9 | 28 | 831 1999 JOURNAL OF NEURO-ONCOLOGY 43(2):109-114 Moreira AL; Friedlander DR; Shif B; Kaplan G; Zagzag D Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro | 22 | 37 |
146 | 15 | 25 | 999 2000 JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY 14(3):140-147 Teo SK; Sabourin PJ; O'Brien K; Kook KA; Thomas SD Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients | 22 | 22 |
147 | 12 | 56 | 1173 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 22 | 32 |
148 | 59 | 87 | 1188 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
149 | 6 | 20 | 1483 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 22 | 36 |
150 | 4 | 25 | 64 1983 ARCHIVES OF DERMATOLOGY 119(10):812-815 HASPER MF CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS - THALIDOMIDE TREATMENT OF 11 PATIENTS | 21 | 32 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
151 | 0 | 0 | 181 1986 CLINICAL RHEUMATOLOGY 5(3):365-371 HAMZA MH TREATMENT OF BEHCETS-DISEASE WITH THALIDOMIDE | 21 | 40 |
152 | 6 | 41 | 193 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
153 | 3 | 3 | 285 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
154 | 20 | 52 | 456 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
155 | 3 | 22 | 532 1996 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 18(1):59-72 Shannon EJ; Sandoval F Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells | 21 | 24 |
156 | 6 | 28 | 654 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
157 | 4 | 13 | 673 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 21 | 32 |
158 | 2 | 5 | 1017 2000 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 21 | 30 |
159 | 51 | 96 | 1049 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
160 | 0 | 0 | 37 1982 ANNALES DE PEDIATRIE 29(1):67-69 VENENCIE PY; SAURAT JH PYODERMA GANGRENOSUM IN A CHILD - TREATMENT WITH THALIDOMIDE | 20 | 36 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
161 | 7 | 26 | 299 1990 TRANSPLANTATION 49(1):20-25 TAMURA F; VOGELSANG GB; REITZ BA; BAUMGARTNER WA; HERSKOWITZ A COMBINATION THALIDOMIDE AND CYCLOSPORINE FOR CARDIAC ALLOGRAFT-REJECTION - COMPARISON WITH COMBINATION METHYLPREDNISOLONE AND CYCLOSPORINE | 20 | 27 |
162 | 0 | 9 | 409 1994 JOURNAL OF CHROMATOGRAPHY A 666(1-2):235-240 KNOCHE B; BLASCHKE G INVESTIGATIONS ON THE IN-VITRO RACEMIZATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 20 | 31 |
163 | 2 | 23 | 419 1994 NEPHRON 67(3):270-273 SILVA SRB; VIANA PCF; LUGON NV; HOETTE M; RUZANY F; LUGON JR THALIDOMIDE FOR THE TREATMENT OF UREMIC PRURITUS - A CROSSOVER RANDOMIZED DOUBLE-BLIND TRIAL | 20 | 43 |
164 | 9 | 31 | 455 1995 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 49(1-2):1-6 HARLAND CC; STEVENTON GB; MARSDEN JR THALIDOMIDE INDUCED NEUROPATHY AND GENETIC-DIFFERENCES IN DRUG-METABOLISM | 20 | 23 |
165 | 3 | 15 | 466 1995 JOURNAL OF INFECTIOUS DISEASES 172(4):1137-1140 PETERSON PK; HU SX; SHENG WS; KRAVITZ FH; MOLITOR TW; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED AND LIPOARABINOMANNAN-STIMULATED HUMAN MICROGLIAL CELLS | 20 | 33 |
166 | 5 | 14 | 498 1996 ANNALS OF THE RHEUMATIC DISEASES 55(11):833-836 Huizinga TWJ; Dijkmans BAC; vanderVelde EA; Kraan TCTMV; Verweij CL; Breedveld FC An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis | 20 | 37 |
167 | 9 | 21 | 609 1997 INTERNATIONAL JOURNAL OF ONCOLOGY 10(5):965-969 Nguyen M; Tran C; Barsky S; Sun JR; McBride W; Pegram M; Pietras R; Love S; Glaspy J Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies | 20 | 26 |
168 | 30 | 53 | 753 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
169 | 3 | 12 | 1157 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 20 | 30 |
170 | 0 | 7 | 36 1982 ACTA DERMATO-VENEREOLOGICA 62(5):449-450 BAHMER FA; ZAUN H; LUSZPINSKI P THALIDOMIDE TREATMENT OF RECURRENT ERYTHEMA MULTIFORME | 19 | 25 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
171 | 1 | 2 | 72 1983 BRITISH MEDICAL JOURNAL 287(6395):799-800 BOWERS PW; POWELL RJ EFFECT OF THALIDOMIDE ON OROGENITAL ULCERATION | 19 | 25 |
172 | 1 | 7 | 200 1986 TRANSPLANTATION PROCEEDINGS 18(4):904-906 VOGELSANG GB; TAYLOR S; GORDON G; HESS AD THALIDOMIDE, A POTENT AGENT FOR THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 19 | 27 |
173 | 2 | 2 | 238 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
174 | 4 | 14 | 281 1990 JOURNAL OF INTERNAL MEDICINE 228(4):405-407 LARSSON H TREATMENT OF SEVERE COLITIS IN BEHCETS-SYNDROME WITH THALIDOMIDE (CG-217) | 19 | 35 |
175 | 8 | 15 | 826 1999 JOURNAL OF CLINICAL PHARMACOLOGY 39(11):1162-1168 Teo SK; Colburn WA; Thomas SD Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers | 19 | 19 |
176 | 16 | 37 | 1147 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 19 | 31 |
177 | 4 | 23 | 1322 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 19 | 33 |
178 | 15 | 35 | 1463 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |
179 | 0 | 2 | 40 1982 ARCHIVES OF DERMATOLOGY 118(11):875-875 TORRAS H; LECHA M; MASCARO JM THALIDOMIDE TREATMENT OF RECURRENT NECROTIC GIANT MUCOCUTANEOUS APHTHAE AND APHTHOSIS | 18 | 24 |
180 | 2 | 13 | 283 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(3):523-525 RADEFF B; KUFFER R; SAMSON J RECURRENT APHTHOUS ULCER IN PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 18 | 30 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
181 | 2 | 4 | 392 1994 BRITISH MEDICAL JOURNAL 308(6944):1635-1636 MCBRIDE WG THALIDOMIDE MAY BE A MUTAGEN | 18 | 24 |
182 | 6 | 11 | 514 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
183 | 8 | 21 | 604 1997 IMMUNOPHARMACOLOGY 36(1):9-15 Shannon EJ; Sandoval F; Krahenbuhl JL Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha | 18 | 19 |
184 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
185 | 2 | 6 | 943 2000 BONE MARROW TRANSPLANTATION 25(12):1319-1320 Zomas A; Anagnostopoulos N; Dimopoulos MA Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent | 18 | 32 |
186 | 12 | 44 | 1007 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
187 | 5 | 12 | 1151 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
188 | 6 | 48 | 1268 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
189 | 0 | 20 | 35 1982 ACTA DERMATO-VENEREOLOGICA 62(4):321-324 HASPER MF; KLOKKE AH THALIDOMIDE IN THE TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS | 17 | 23 |
190 | 0 | 13 | 103 1984 ACTA DERMATO-VENEREOLOGICA 64(5):412-417 WINKELMANN RK; CONNOLLY SM; DOYLE JA; PADILHAGONCALVES A THALIDOMIDE TREATMENT OF PRURIGO NODULARIS | 17 | 27 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
191 | 0 | 7 | 246 1988 TERATOLOGY 38(3):221-226 KELSEY FO THALIDOMIDE UPDATE - REGULATORY ASPECTS | 17 | 29 |
192 | 11 | 38 | 287 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
193 | 1 | 20 | 312 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
194 | 8 | 13 | 349 1993 ARCHIVES OF DERMATOLOGY 129(12):1548-1550 HOLM AL; BOWERS KE; MCMEEKIN TO; GASPARI AA CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS TREATED WITH THALIDOMIDE | 17 | 20 |
195 | 9 | 14 | 432 1995 ANNALS OF CLINICAL BIOCHEMISTRY 32:79-83 BOUGHTON BJ; SHEEHAN TMT; WOOD J; OBRIEN D; BUTLER M; SIMPSON A; HALE KA HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY OF PLASMA THALIDOMIDE - STABILIZATION OF SPECIMENS AND DETERMINATION OF A TENTATIVE THERAPEUTIC RANGE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 17 | 17 |
196 | 28 | 50 | 589 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
197 | 1 | 3 | 626 1997 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 25(2):250-251 Odeka EB; Miller V Thalidomide in oral Crohn's disease refractory to conventional medical treatment | 17 | 0 |
198 | 21 | 108 | 634 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
199 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
200 | 10 | 23 | 688 1998 CHIRALITY 10(3):223-228 Eriksson T; Bjorkman S; Roth B; Fyge A; Hoglund P Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis | 17 | 28 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
201 | 4 | 42 | 785 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
202 | 17 | 32 | 887 2000 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 44(9):2286-2290 Verbon A; Juffermans NP; Speelman P; van Deventer SJH; ten Berge IJM; Guchelaar HJ; van der Poll T A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans | 17 | 18 |
203 | 9 | 41 | 1057 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
204 | 7 | 22 | 1223 2001 JOURNAL OF CLINICAL ONCOLOGY 19(16):3596-3601 Dimopoulos MA; Zomas A; Viniou NA; Grigoraki V; Galani E; Matsouka C; Economou O; Anagnostopoulos N; Panayiotidis P Treatment of Waldenstrom's macroglobulinemia with thalidomide | 17 | 28 |
205 | 53 | 61 | 1307 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 17 | 21 |
206 | 33 | 37 | 1421 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 17 | 19 |
207 | 0 | 8 | 6 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 271(2):165-170 KNOP J; HAPPLE R; BONSMANN G; VAKILZADEH F; MACHER E TREATMENT OF CHRONIC DISCOID LUPUS-ERYTHEMATOSUS WITH THALIDOMIDE | 16 | 17 |
208 | 41 | 106 | 267 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
209 | 10 | 24 | 433 1995 ANNALS OF THORACIC SURGERY 59(2):277-282 UTHOFF K; ZEHR KJ; GAUDIN PB; KUMAR P; CHO PW; VOGELSANG G; HRUBAN RH; BAUMGARTNER WA; STUART RS THALIDOMIDE AS REPLACEMENT FOR STEROIDS IN IMMUNOSUPPRESSION AFTER LUNG TRANSPLANTATION | 16 | 18 |
210 | 3 | 25 | 500 1996 ANTICANCER RESEARCH 16(6B):3673-3677 Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo | 16 | 23 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
211 | 7 | 24 | 684 1998 BRITISH JOURNAL OF CANCER 78(3):336-343 Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity | 16 | 27 |
212 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
213 | 10 | 33 | 716 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 16 | 32 |
214 | 3 | 8 | 754 1999 ARTHRITIS AND RHEUMATISM 42(3):580-581 Breban M; Gombert B; Amor B; Dougados M Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis | 16 | 53 |
215 | 6 | 24 | 879 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
216 | 45 | 95 | 965 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
217 | 18 | 27 | 992 2000 INTERNATIONAL JOURNAL OF DERMATOLOGY 39(5):383-388 Walchner M; Meurer M; Plewig G; Messer G Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus | 16 | 27 |
218 | 6 | 16 | 1074 2001 ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 27 |
219 | 8 | 40 | 1269 2001 SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 16 | 38 |
220 | 4 | 24 | 109 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
221 | 0 | 4 | 203 1987 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 114(11):1387-1389 GNASSIA AM; GNASSIA RT; BONVALET D; PUISSANT A; GOUDAL H HISTIOCYTOSIS-X WITH VULVAR LOCALIZATION - DRAMATIC EFFECT OF THALIDOMIDE | 15 | 23 |
222 | 10 | 23 | 253 1989 BIOMEDICINE & PHARMACOTHERAPY 43(9):693-697 MCCARTHY DM; KANFER EJ; BARRETT AJ THALIDOMIDE FOR THE THERAPY OF GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION | 15 | 17 |
223 | 0 | 12 | 400 1994 CHIRALITY 6(4):221-224 KNOCHE B; BLASCHKE G STEREOSELECTIVITY OF THE IN-VITRO METABOLISM OF THALIDOMIDE | 15 | 19 |
224 | 2 | 3 | 501 1996 ARCHIVES OF DERMATOLOGY 132(11):1392-1393 Dereure O; BassetSeguin N; Guilhou JJ Erosive lichen planus: Dramatic response to thalidomide | 15 | 25 |
225 | 5 | 21 | 508 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
226 | 11 | 41 | 686 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
227 | 6 | 12 | 750 1999 ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 15 | 31 |
228 | 1 | 3 | 942 2000 BLOOD 96(12):4007-4007 Tefferi A; Elliott MA Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia | 15 | 24 |
229 | 17 | 27 | 1015 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
230 | 12 | 35 | 1171 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
231 | 7 | 29 | 1231 2001 JOURNAL OF NEURO-ONCOLOGY 54(1):31-38 Marx GM; Pavlakis N; McCowatt S; Boyle FM; Levi JA; Bell DR; Cook R; Biggs M; Little N; Wheeler HR Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme | 15 | 22 |
232 | 7 | 22 | 1517 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 15 | 26 |
233 | 19 | 50 | 1676 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 15 | 18 |
234 | 2 | 25 | 38 1982 ARCHIVES OF DERMATOLOGICAL RESEARCH 274(3-4):363-367 MIYACHI Y; OZAKI M; UCHIDA K; NIWA Y EFFECTS OF THALIDOMIDE ON THE GENERATION OF OXYGEN INTERMEDIATES BY ZYMOSAN-STIMULATED NORMAL POLYMORPHONUCLEAR LEUKOCYTES | 14 | 22 |
235 | 4 | 8 | 249 1988 TRANSPLANTATION PROCEEDINGS 20(2):226-228 VOGELSANG GB; WELLS MC; SANTOS GW; CHEN TL; HESS AD COMBINATION LOW-DOSE THALIDOMIDE AND CYCLOSPORINE PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN A RAT MISMATCHED MODEL | 14 | 16 |
236 | 3 | 13 | 284 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(5):941-944 RUSTIN MHA; GILKES JJH; ROBINSON TWE PYODERMA-GANGRENOSUM ASSOCIATED WITH BEHCETS-DISEASE - TREATMENT WITH THALIDOMIDE | 14 | 27 |
237 | 8 | 25 | 381 1994 ARCHIVES OF DERMATOLOGICAL RESEARCH 286(6):347-349 TSAMBAOS D; BOLSEN K; GEORGIOU S; MONASTIRLI A; GOERZ G EFFECTS OF ORAL THALIDOMIDE ON RAT-LIVER AND SKIN MICROSOMAL P450 ISOZYME ACTIVITIES AND ON URINARY PORPHYRIN EXCRETION - INTERACTION WITH ORAL HEXACHLOROBENZENE | 14 | 15 |
238 | 1 | 5 | 430 1995 AIDS 9(6):658-659 SHARPSTONE D; ROWBOTTOM A; NELSON M; GAZZARD B THE TREATMENT OF MICROSPORIDIAL DIARRHEA WITH THALIDOMIDE | 14 | 34 |
239 | 3 | 6 | 471 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 14 | 23 |
240 | 8 | 17 | 562 1996 TERATOLOGY 54(6):273-277 Castilla EE; AshtonProlla P; BarredaMejia E; Brunoni D; Cavalcanti DP; CorreaNeto J; Delgadillo JL; Dutra MG; Felix T; Giraldo A; Juarez N; LopezCamelo JS; Nazer J; Orioli IM; Paz JE; Pessoto MA; PinaNeto JM; Quadrelli R; Rittler M; Rueda S; Saltos M; Sanchez O; Schuler L Thalidomide, a current teratogen in South America | 14 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
241 | 9 | 41 | 710 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
242 | 9 | 14 | 717 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
243 | 10 | 18 | 719 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
244 | 66 | 87 | 742 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
245 | 10 | 15 | 835 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 18 |
246 | 3 | 14 | 874 2000 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS 23(3):319-321 Patt YZ; Hassan MM; Lozano RD; Ellis LM; Peterson JA; Waugh KA Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide | 14 | 26 |
247 | 4 | 8 | 941 2000 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
248 | 3 | 19 | 1142 2001 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 14 | 22 |
249 | 8 | 53 | 1158 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 14 | 23 |
250 | 12 | 35 | 1321 2002 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 14 | 54 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
251 | 25 | 54 | 1425 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 14 | 15 |
252 | 23 | 42 | 1495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
253 | 1 | 36 | 90 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
254 | 2 | 2 | 143 1985 BRITISH JOURNAL OF DERMATOLOGY 112(5):632-632 KURKCUOGLU N; ATAKAN N; EKSIOGLU M THALIDOMIDE IN THE TREATMENT OF RECURRENT NECROTIC MUCOCUTANEOUS APHTHAE | 13 | 16 |
255 | 1 | 6 | 316 1992 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 119(4):281-283 BENSAID P; MACHET L; VAILLANT L; MACHET MC; SCOTTO B; LORETTE G ADULT LANGERHANS-CELL HISTIOCYTOSIS - REGRESSION OF PAROTID-GLAND INVOLVEMENT AFTER THALIDOMIDE TREATMENT | 13 | 18 |
256 | 14 | 22 | 402 1994 DERMATOLOGY 189(2):179-181 BIELSA I; TEIXIDO J; RIBERA M; FERRANDIZ C ERYTHRODERMA DUE TO THALIDOMIDE - REPORT OF 2 CASES | 13 | 17 |
257 | 7 | 14 | 509 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 226(2):439-444 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence | 13 | 20 |
258 | 6 | 13 | 668 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 13 | 20 |
259 | 8 | 27 | 693 1998 CLINICAL PHARMACOLOGY & THERAPEUTICS 64(6):597-602 Trapnell CB; Donahue SR; Collins JM; Flockhart DA; Thacker D; Abernethy DR Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone | 13 | 15 |
260 | 22 | 30 | 745 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(12):1047-1052 Noormohamed FH; Youle MS; Higgs CJ; Kook KA; Hawkins DA; Lant AF; Thomas SD Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects | 13 | 13 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
261 | 29 | 79 | 751 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
262 | 13 | 32 | 873 2000 AIDS RESEARCH AND HUMAN RETROVIRUSES 16(14):1345-1355 Kaplan G; Thomas S; Fierer DS; Mulligan K; Haslett PAJ; Fessel WJ; Smith LG; Kook KA; Stirling D; Schambelan M Thalidomide for the treatment of AIDS-associated wasting | 13 | 28 |
263 | 12 | 22 | 1152 2001 BRITISH JOURNAL OF HAEMATOLOGY 114(1):78-83 Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia | 13 | 24 |
264 | 17 | 33 | 1202 2001 HAEMATOLOGICA 86(4):409-413 Tosi P; Ronconi S; Zamagni E; Cellini C; Grafone T; Cangini D; Pileri SA; Baccarani M; Tura S; Cavo M Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation | 13 | 21 |
265 | 5 | 5 | 1318 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 13 | 18 |
266 | 12 | 36 | 1400 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 13 | 23 |
267 | 2 | 17 | 63 1983 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 110(8):611-614 MOULIN G; BONNET F; BARRUT D; FRANC MP TREATMENT OF JESSNER-KANOF DISEASE WITH THALIDOMIDE | 12 | 21 |
268 | 0 | 2 | 94 1983 PRESSE MEDICALE 12(15):963-963 BARRIERE H SARCOIDOSIS OF THE SKIN - TREATMENT WITH THALIDOMIDE | 12 | 16 |
269 | 5 | 17 | 230 1988 CLINICAL AND EXPERIMENTAL DERMATOLOGY 13(6):408-410 MUNRO CS; COX NH PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCETS SYNDROME - RESPONSE TO THALIDOMIDE | 12 | 19 |
270 | 2 | 6 | 236 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
271 | 19 | 39 | 270 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
272 | 2 | 34 | 300 1991 BRITISH JOURNAL OF DERMATOLOGY 125(1):62-67 BURROWS NP; WALPORT MJ; HAMMOND AH; DAVEY N; JONES RR LUPUS-ERYTHEMATOSUS PROFUNDUS WITH PARTIAL C4-DEFICIENCY RESPONDING TO THALIDOMIDE | 12 | 23 |
273 | 1 | 5 | 328 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
274 | 0 | 3 | 393 1994 BRITISH MEDICAL JOURNAL 308(6944):1636-1636 READ AP THALIDOMIDE MAY BE A MUTAGEN - COMMENT | 12 | 14 |
275 | 7 | 19 | 435 1995 ARCHIVES OF DERMATOLOGY 131(9):1032-1035 GUILLAUME JC; MOULIN G; DIENG MT; POLI F; MOREL P; SOUTEYRAND P; BONNETBLANC JM; CLAUDY A; DANIEL F; VAILLANT L; BERNARD P; BOUILLIE MC; BOURNERIAS I; DENOEUX JP; LAMBERT D; LEONARD F; CHAUMEIL JC; REVUZ J CROSSOVER STUDY OF THALIDOMIDE VS PLACEBO IN JESSNERS LYMPHOCYTIC INFILTRATION OF THE SKIN | 12 | 17 |
276 | 2 | 14 | 525 1996 EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 8(9):929-931 Postema PTE; denHaan P; vanHagen PM; vanBlankenstein M Treatment of colitis in Behcet's disease with thalidomide | 12 | 20 |
277 | 10 | 11 | 570 1997 AMERICAN JOURNAL OF GASTROENTEROLOGY 92(1):169-170 Ball SC; Sepkowitz KA; Jacobs JL Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: Case report and review | 12 | 13 |
278 | 11 | 39 | 602 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
279 | 8 | 59 | 635 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
280 | 4 | 5 | 664 1998 ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
281 | 2 | 4 | 738 1998 PALLIATIVE MEDICINE 12(3):208-209 Deaner P Thalidomide for distressing night sweats in advanced malignant disease | 12 | 13 |
282 | 8 | 27 | 794 1999 CLINICAL PHARMACOLOGY & THERAPEUTICS 65(5):483-490 Scheffler MR; Colburn W; Kook KA; Thomas SD Thalidomide does not alter estrogen-progesterone hormone single-dose pharmacokinetics | 12 | 12 |
283 | 13 | 40 | 867 1999 SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
284 | 50 | 73 | 1086 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
285 | 2 | 12 | 1155 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 12 | 17 |
286 | 40 | 53 | 1189 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 12 | 16 |
287 | 9 | 23 | 1230 2001 JOURNAL OF NEURO-ONCOLOGY 51(1):41-45 Short SC; Traish D; Dowe A; Hines F; Gore M; Brada M Thalidomide as an anti-angiogenic agent in relapsed gliomas | 12 | 22 |
288 | 13 | 29 | 1244 2001 MUSCLE & NERVE 24(8):1050-1057 Molloy FM; Floeter MK; Syed NA; Sandbrink F; Culcea E; Steinberg SM; Dahut W; Pluda J; Kruger EA; Reed E; Figg WD Thalidomide neuropathy in patients treated for metastatic prostate cancer | 12 | 17 |
289 | 6 | 28 | 1294 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 12 | 23 |
290 | 8 | 30 | 1315 2002 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 12 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
291 | 6 | 26 | 1488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
292 | 37 | 67 | 1494 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 25 |
293 | 12 | 32 | 1780 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 12 | 19 |
294 | 0 | 0 | 5 1981 ARCHIVES OF DERMATOLOGICAL RESEARCH 270(2):229-229 KNOP J; HAPPLE R; VAKILZADEH F; MACHER E TREATMENT OF LUPUS-ERYTHEMATOSUS PROFUNDUS WITH THALIDOMIDE | 11 | 13 |
295 | 3 | 12 | 171 1985 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 5(3):149-158 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES | 11 | 15 |
296 | 4 | 10 | 325 1992 JOURNAL OF INFECTIOUS DISEASES 166(4):939-940 GEORGHIOU PR; ALLWORTH AM THALIDOMIDE IN PAINFUL AIDS-ASSOCIATED PROCTITIS | 11 | 21 |
297 | 3 | 3 | 358 1993 CLINICAL AND EXPERIMENTAL DERMATOLOGY 18(5):487-487 MISERY L; LARBRE B; LYONNET S; FAURE M; THIVOLET J REMISSION OF LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE TREATMENT | 11 | 18 |
298 | 3 | 19 | 465 1995 JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS 674(2):287-292 Weinz C; Blaschke G Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis | 11 | 24 |
299 | 3 | 5 | 502 1996 ARCHIVES OF DISEASE IN CHILDHOOD 74(1):64-65 Soler RA; Migliorati C; vanWaes H; Nadal D Thalidomide treatment of mucosal ulcerations in HIV infection | 11 | 14 |
300 | 6 | 35 | 582 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |